Junji Tsurutani Selected Research

Topoisomerase I Inhibitors

10/2017	DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
4/2013	Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
2/2005	Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
12/2004	Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
8/2003	Expression and functional analyses of breast cancer resistance protein in lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Junji Tsurutani Research Topics

Disease

54	Neoplasms (Cancer) 05/2022 - 01/2002
44	Breast Neoplasms (Breast Cancer) 05/2022 - 08/2003
27	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2021 - 01/2002
13	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2002
8	Interstitial Lung Diseases (Interstitial Lung Disease) 05/2022 - 02/2010
8	Disease Progression 01/2022 - 11/2010
8	Stomach Neoplasms (Stomach Cancer) 12/2021 - 12/2016
7	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2006 - 03/2003
6	Colorectal Neoplasms (Colorectal Cancer) 12/2019 - 03/2010
5	Pain (Aches) 10/2017 - 12/2011
5	Neoplasm Metastasis (Metastasis) 09/2017 - 02/2011
5	Neutropenia 01/2016 - 10/2010
4	Pneumonia (Pneumonitis) 05/2022 - 01/2016
4	Fatigue 01/2022 - 02/2010
4	Peripheral Nervous System Diseases (PNS Diseases) 02/2021 - 03/2019
3	Triple Negative Breast Neoplasms 01/2022 - 01/2014
3	Urinary Bladder Neoplasms (Bladder Cancer) 12/2021 - 09/2019
3	Carcinoma (Carcinomatosis) 06/2021 - 10/2017
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2020
3	Cancer Pain 10/2017 - 01/2017
3	Alopecia (Baldness) 02/2015 - 02/2010
3	Diarrhea 10/2014 - 10/2010
2	Infections 05/2022 - 03/2017
2	Lung Injury 05/2022 - 08/2019
2	Melanoma (Melanoma, Malignant) 02/2021 - 01/2016
2	Inflammation (Inflammations) 08/2019 - 03/2017
2	Adenocarcinoma of Lung 01/2019 - 01/2019
2	Brain Neoplasms (Brain Tumor) 03/2016 - 12/2013
2	Hypersensitivity (Allergy) 06/2011 - 02/2010

Drug/Important Bio-Agent (IBA)

15	Pharmaceutical PreparationsIBA 05/2022 - 03/2003
14	ErbB Receptors (EGF Receptor)IBA 01/2022 - 05/2003
10	trastuzumab deruxtecanIBA 05/2022 - 10/2017
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2007
10	eribulin FDA Link 07/2021 - 12/2013
10	Tyrosine Kinase InhibitorsIBA 08/2019 - 05/2003
9	Irinotecan (Camptosar)FDA LinkGeneric 05/2021 - 03/2002
9	Gefitinib (Iressa)FDA Link 08/2019 - 12/2004
8	taxaneIBA 01/2022 - 04/2013
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2003
8	Trastuzumab (Herceptin)FDA Link 05/2020 - 07/2014
6	human ERBB2 proteinIBA 05/2022 - 08/2018
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2002
6	Messenger RNA (mRNA)IBA 01/2021 - 03/2003
6	Opioid Analgesics (Opioids)IBA 10/2017 - 12/2011
5	Immunoconjugates (Immunoconjugate)IBA 05/2022 - 10/2017
5	Hormones (Hormone)IBA 01/2022 - 01/2020
5	Immune Checkpoint InhibitorsIBA 12/2021 - 09/2019
5	Ado-Trastuzumab EmtansineIBA 01/2020 - 12/2016
5	Topoisomerase I InhibitorsIBA 10/2017 - 08/2003
5	Morphine (MS Contin)FDA LinkGeneric 10/2017 - 12/2011
4	130-nm albumin-bound paclitaxelIBA 01/2022 - 06/2015
4	Alanine Transaminase (SGPT)IBA 06/2021 - 07/2014
4	Pemetrexed (MTA)FDA Link 06/2019 - 11/2010
4	Lapatinib (GW572016)FDA Link 08/2018 - 04/2011
3	NivolumabIBA 01/2022 - 05/2021
3	Bevacizumab (Avastin)FDA Link 01/2022 - 01/2019
3	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 03/2002
3	Epidermal Growth Factor (EGF)IBA 10/2021 - 07/2014
3	Formaldehyde (Formol)FDA Link 10/2021 - 01/2015
3	ParaffinIBA 10/2021 - 01/2015
3	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 01/2004
3	Capecitabine (Xeloda)FDA Link 08/2021 - 12/2013
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 06/2021 - 02/2015
3	osimertinibIBA 10/2020 - 01/2019
3	pertuzumabIBA 05/2020 - 01/2019
3	Taxoids (Taxanes)IBA 05/2020 - 01/2016
3	AnthracyclinesIBA 10/2019 - 04/2013
3	Sirolimus (Rapamycin)FDA Link 06/2019 - 04/2007
3	AfatinibIBA 01/2019 - 03/2016
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 06/2012
3	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 10/2017 - 05/2012
3	Fluorouracil (Carac)FDA LinkGeneric 09/2017 - 02/2011
3	Adenosine Triphosphate (ATP)IBA 09/2005 - 08/2003
3	Mitoxantrone (Novantrone)FDA LinkGeneric 02/2005 - 08/2003
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2022 - 12/2011
2	LigandsIBA 01/2022 - 01/2019
2	AntibodiesIBA 12/2021 - 01/2015
2	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 01/2016
2	Estrogen ReceptorsIBA 10/2021 - 09/2018
2	TubulinIBA 10/2021 - 01/2002
2	Indicators and Reagents (Reagents)IBA 12/2020 - 05/2012
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2019 - 05/2003
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2019 - 06/2011
2	Neuregulin-1 (Neuregulin 1)IBA 01/2019 - 12/2016
2	Circulating Tumor DNAIBA 09/2018 - 01/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2017 - 08/2003
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2017 - 02/2011
2	Epirubicin (Ellence)FDA LinkGeneric 09/2017 - 02/2011
2	Gemcitabine FDA Link 01/2017 - 10/2010
2	Monoclonal AntibodiesIBA 01/2016 - 04/2015
2	Docetaxel (Taxotere)FDA Link 02/2015 - 02/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 03/2002
2	Carboplatin (JM8)FDA LinkGeneric 11/2010 - 12/2004
2	CarcinogensIBA 04/2007 - 07/2005

Therapy/Procedure

34	Therapeutics 01/2022 - 01/2007
25	Drug Therapy (Chemotherapy) 05/2022 - 03/2002
5	Radiotherapy 10/2017 - 02/2011
3	Immunotherapy 10/2021 - 01/2019
3	Aftercare (After-Treatment) 01/2020 - 10/2017
2	Duration of Therapy 09/2017 - 06/2011